Aptar Pharma Buys Pulmotree to Boost Pulmonary Drug Delivery
Aptar Pharma has acquired Pulmotree, a move aimed at accelerating its position in next-generation pulmonary drug delivery technology.
Crystal Lake, Ill.-based Aptar Pharma announced Wednesday the acquisition of Pulmotree, a strategic move the company says will expand its capabilities and growth opportunities in next-generation pulmonary drug delivery systems. The deal signals Aptar's intent to deepen its foothold in an increasingly competitive inhaled therapeutics market.
Pulmonary drug delivery — which includes inhalers and nebulizers used to treat conditions such as asthma, COPD, and other respiratory diseases — has emerged as one of the fastest-evolving segments in pharmaceutical device manufacturing. Companies that control proprietary delivery platforms hold significant leverage with drugmakers seeking reliable, regulatory-compliant partners.
Read more Bon Secours to Acquire Surgery Partners in $5.7B Deal →
By absorbing Pulmotree's technology and expertise, Aptar Pharma positions itself to offer customers more advanced solutions for getting drugs efficiently into patients' lungs. Such acquisitions are a common growth mechanism in the pharma device space, where organic R&D timelines can stretch years and buying proven platforms accelerates market readiness.
Aptar Pharma operates as the pharmaceutical division of AptarGroup, a global leader in drug delivery, consumer product dispensing, and active packaging solutions. The Pulmotree acquisition adds to a broader portfolio that already spans nasal, inhalation, ophthalmic, and injectable delivery formats, reinforcing the parent company's strategy of expanding through targeted bolt-on deals in high-growth therapeutic areas.
Continue reading at BusinessWire.
